Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles Annals of Oncology Year : 2022

Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy

Dates and versions

hal-03940635 , version 1 (16-01-2023)

Identifiers

Cite

Younes Belkouchi, Hugues Talbot, Nathalie Lassau, L. Lawrance, S. Farhane, et al.. Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy. Annals of Oncology, 2022, 33, pp.S595-S596. ⟨10.1016/j.annonc.2022.07.159⟩. ⟨hal-03940635⟩
64 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More